Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2014 Sep 25

PMID 25252033

Citations 20

Authors

Hiromi Kan

Sho-Ichi Yamagishi

Ayako Ojima

Kei Fukami

Seiji Ueda

Masayoshi Takeuchi

Hideyuki Hyogo

Hiroshi Aikata

Kazuaki Chayama

Affiliations

Soon will be listed here.

Abstract

Background: The prevalence of non-B or non-C hepatocellular carcinoma (NBNC-HCC) has been increasing all over the world. Advanced glycation end products (AGE) play a role in the pathogenesis of alcoholic liver injury or nonalcoholic steatohepatitis (NASH).

Methods: We examined here whether serum levels of AGE were elevated in NBNC-HCC patients compared with NASH subjects without HCC and investigated which anthropometric and clinical variables were independent determinants of AGE.

Results: Ninety NBNC-HCC, 56 NASH, and 27 control subjects underwent a complete history and physical examination, determination of blood chemistries, including AGE levels. Serum levels of AGE were significantly higher in NBNC-HCC patients compared with NASH and control subjects [9.1 ± 2.7, 5.2 ± 1.7, 3.5 ± 1.2 (U/ml), respectively, P < 0.05]. Univariate analysis showed that AGE levels were associated with male (P < 0.05), age (P < 0.01), aspartate aminotransferase (P < 0.05), γ-glutamyl transpeptidase (GGT) (P < 0.01), HDL-cholesterol (inversely, P < 0.01), fasting plasma glucose (P < 0.01), and HbA1c (P < 0.05). By the use of multiple stepwise regression analysis, age, GGT, and HDL-cholesterol (inversely) remained significant and were independently related to AGE levels (R(2) = 0.406).

Conclusion: The present results suggest that AGE might be involved in the pathogenesis of NBNC-HCC, thereby being a biomarker that could discriminate NBNC-HCC from NASH.

Citing Articles

Associations of circulating advanced glycation end products and their soluble receptors with cancer risk: A systematic review and meta-analysis of observational studies.

Hajizadeh-Sharafabad F, Shojaei-Zarghani S, Sharifi-Zahabi E, Gerami F, Pashaei M Glycoconj J. 2024; 41(1):35-46.

PMID: 38498243 DOI: 10.1007/s10719-024-10147-w.

Plasma pentosidine as a useful biomarker of sarcopenia, low gait speed, and mortality in patients with cirrhosis.

Saeki C, Saito M, Tsubota A Front Med (Lausanne). 2023; 10:1212899.

PMID: 37780552 PMC: 10541311. DOI: 10.3389/fmed.2023.1212899.

Anti-Fibrotic Effects of DL-Glyceraldehyde in Hepatic Stellate Cells via Activation of ERK-JNK-Caspase-3 Signaling Axis.

Md Samsuzzaman , Kim S Biomol Ther (Seoul). 2023; 31(4):425-433.

PMID: 37035877 PMC: 10315341. DOI: 10.4062/biomolther.2022.131.

Involvement of Intracellular TAGE and the TAGE-RAGE-ROS Axis in the Onset and Progression of NAFLD/NASH.

Sakasai-Sakai A, Takeda K, Takeuchi M Antioxidants (Basel). 2023; 12(3).

PMID: 36978995 PMC: 10045097. DOI: 10.3390/antiox12030748.

Effects of Toxic AGEs (TAGE) on Human Health.

Takeuchi M, Sakasai-Sakai A, Takata T, Takino J, Koriyama Y Cells. 2022; 11(14).

PMID: 35883620 PMC: 9317028. DOI: 10.3390/cells11142178.

References

Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K . Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012; 47(5):586-95. DOI: 10.1007/s00535-012-0533-z. View

Iwamoto K, Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S . Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. J Gastroenterol. 2008; 43(4):298-304. DOI: 10.1007/s00535-007-2152-7. View

Hayashi N, George J, Takeuchi M, Fukumura A, Toshikuni N, Arisawa T . Acetaldehyde-derived advanced glycation end-products promote alcoholic liver disease. PLoS One. 2013; 8(7):e70034. PMC: 3724722. DOI: 10.1371/journal.pone.0070034. View

El-Serag H . Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142(6):1264-1273.e1. PMC: 3338949. DOI: 10.1053/j.gastro.2011.12.061. View

Vlassara H, Palace M . Diabetes and advanced glycation endproducts. J Intern Med. 2002; 251(2):87-101. DOI: 10.1046/j.1365-2796.2002.00932.x. View

Zhang J, Chen Y, Zhang B, Xie X, Zhang L, Ge N . Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2011; 23(9):787-93. DOI: 10.1097/MEG.0b013e32834902dd. View

Matteoni C, Younossi Z, Gramlich T, Boparai N, Liu Y, McCullough A . Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116(6):1413-9. DOI: 10.1016/s0016-5085(99)70506-8. View

Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S . Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003; 38(10):954-61. DOI: 10.1007/s00535-003-1178-8. View

Takuma Y, Nouso K, Makino Y, Gotoh T, Toshikuni N, Morimoto Y . Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria. J Gastroenterol Hepatol. 2011; 26(9):1417-24. DOI: 10.1111/j.1440-1746.2011.06775.x. View

10.

Yamagishi S, Maeda S, Matsui T, Ueda S, Fukami K, Okuda S . Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta. 2011; 1820(5):663-71. DOI: 10.1016/j.bbagen.2011.03.014. View

11.

Bosch F, Ribes J, Diaz M, Cleries R . Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004; 127(5 Suppl 1):S5-S16. DOI: 10.1053/j.gastro.2004.09.011. View

12.

Ju M, Qiu S, Fan J, Zhou J, Gao Q, Cai M . Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009; 44(6):635-42. DOI: 10.1007/s00535-009-0050-x. View

13.

Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K . The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005; 143(10):722-8. DOI: 10.7326/0003-4819-143-10-200511150-00009. View

14.

Morsi M, Hussein A, Mostafa M, El-Abd E, Abd El-Moneim N . Evaluation of tumour necrosis factor-alpha, soluble P-selectin, gamma-glutamyl transferase, glutathione S-transferase-pi and alpha-fetoprotein in patients with hepatocellular carcinoma before and during chemotherapy. Br J Biomed Sci. 2006; 63(2):74-8. DOI: 10.1080/09674845.2006.11732724. View

15.

Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T . Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res. 2011; 42(4):368-75. DOI: 10.1111/j.1872-034X.2011.00929.x. View

16.

Yamagishi S . Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets. 2011; 12(14):2096-102. DOI: 10.2174/138945011798829456. View

17.

Kaibori M, Ishizaki M, Matsui K, Kwon A . Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy. Am J Surg. 2012; 204(3):300-7. DOI: 10.1016/j.amjsurg.2011.11.014. View

18.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

19.

Teli M, James O, Burt A, Bennett M, Day C . The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995; 22(6):1714-9. View

20.

Okanoue T, Umemura A, Yasui K, Itoh Y . Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol Hepatol. 2011; 26 Suppl 1:153-62. DOI: 10.1111/j.1440-1746.2010.06547.x. View